Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative PK, Safety, and Immunogenicity Study of KSHB002 (Abatacept) vs ORENCIA in Healthy Volunteers
NCT06929039Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time zero to infinity. Started Jul 2024; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06929039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929039.